Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. - Wikidata - wikimedia - TriplyDB

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

http://www.wikidata.org/entity/Q46396658

about

Retroviral intasome assembly and inhibition of DNA strand transfer Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids Computational methods in drug discovery Exploring the role of receptor flexibility in structure-based drug discovery Allosteric Inhibition of Human Immunodeficiency Virus Integrase Functional and structural characterization of the integrase from the prototype foamy virus Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1 Structural and Binding Analysis of Pyrimidinol Carboxylic Acid and N-Hydroxy Quinazolinedione HIV-1 RNase H Inhibitors Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)Small Molecule Inhibitors of the LEDGF Site of Human Immunodeficiency Virus Integrase Identified by Fragment Screening and Structure Based Design Structural and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease Structural Analysis of Specific Metal Chelating Inhibitor Binding to the Endonuclease Domain of Influenza pH1N1 (2009) Polymerase Assembly of prototype foamy virus strand transfer complexes on product DNA bypassing catalysis of integration Activities, Crystal Structures, and Molecular Dynamics of Dihydro-1 H -isoindole Derivatives, Inhibitors of HIV-1 Integrase Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation 3′-Processing and strand transfer catalysed by retroviral integrasein crystallo Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?Long-term efficacy and safety of raltegravir in the management of HIV infection.A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles Substrate recognition and motion mode analyses of PFV integrase in complex with viral DNA via coarse-grained models Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors Molecular features related to HIV integrase inhibition obtained from structure- and ligand-based approaches Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials Retroviral DNA Integration Molecular dynamics simulations: from structure function relationships to drug discovery.Computational methods in drug discovery.Combinatorial approaches to the prevention and treatment of HIV-1 infection A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay.Molecular modeling study on the allosteric inhibition mechanism of HIV-1 integrase by LEDGF/p75 binding site inhibitors.An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule.4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer.A dynamic model of HIV integrase inhibition and drug resistance.Identifying chelators for metalloprotein inhibitors using a fragment-based approach.

P2860

Q24629737-5D3BD6C3-DAA7-47E8-9203-8E9DB3CCDB15 Q26800036-91C5A254-7364-4A22-9B89-F3BEFB367225 Q26997089-2FCB43D0-DEB9-42E9-A9CE-1778CFE07C54 Q27001129-40181FA9-3964-4359-86A4-85C6D289E90E Q27644578-8456519F-25B5-4363-82F3-E0C486EC0CBE Q27653000-69B6D410-F5FA-4C19-BCB7-39DF88DD7C24 Q27660224-6A89EC94-DA90-4D15-B886-8B3A083BDDB9 Q27664231-7CB10BCC-F6CA-4D81-A5B9-A43386025E4B Q27665427-8231812F-5D2C-403F-9EA8-103D32E7DE58 Q27666603-58618643-86DA-4F65-9499-49F4BBD731DA Q27667421-35AEFDA7-1345-4281-AFF6-19E70DA82B92 Q27670616-8C53BA0F-BF08-43AB-868E-22C9DF67BCCC Q27670782-6E4D4F5E-9E19-4BDC-8584-6754819CD537 Q27671357-38A2BF84-736C-4030-A718-F529584A0FFB Q27671365-26F2C4E9-372D-432D-86C1-E3883018FFC6 Q27673624-96215379-6C69-47E3-87BA-0742DA36BD4B Q27674615-52EDE23D-A8FE-4D5F-B4D8-A6F1A3C4082C Q27677515-27081591-EF10-4B65-98A1-B1EC389FA1B8 Q27679066-D405BA22-6DDD-49E9-942D-EB9FBCDCB958 Q27683344-4DE410EA-F0AF-4974-BB59-A92C19A607AC Q27686870-4F6FFFEB-F518-442D-B705-5B097C17CABC Q27728086-8B739736-1201-4D13-A169-9446D2E85D26 Q28301501-34F65480-DA36-41C2-AFCF-EEC6CD0056EE Q28485284-B0973FD8-3C7C-4EF0-947B-8134647DCA1B Q28533830-DFB2C305-9F95-43A1-A6E1-E14AFBC48A5B Q28538414-C02D0A65-435F-4697-826B-F177F008C472 Q28541754-078D338E-D8BD-4C08-AF5D-8EB93C85C692 Q28553571-761F50AC-E246-476F-B008-C142A1C60F5C Q28596842-ADADA57F-BBBA-4314-B36A-87027D8B1763 Q30369875-FA39C317-E672-40B6-86B8-F24B43560ACB Q30398071-68C82389-6EA6-4FB9-83F2-433F641BAF6C Q30400060-095152D2-D23B-4B4D-AB2B-B55D0CB9CBAB Q30429621-30C4D40A-F796-47C8-9F72-6E76AE9CCA8C Q30574395-A44C1F3A-B413-4C34-8C13-684F445CC78D Q31153312-F2302B2F-48F4-4D08-8C87-95F9DE8E7ABC Q33488152-7171A997-5007-43ED-9BD7-2C045602CEA8 Q33636046-F23278B5-2BC5-4B82-9719-6C981A11A3D5 Q33748099-1A4AD37D-EE28-4901-B238-0A6D73DEDC2E Q33758191-1CE738E5-DEBE-4E95-9241-408752D00258 Q33781388-A6F41757-E4EB-46AF-B809-5D204CC20357

P2860

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

http://www.wikidata.org/entity/Q46396658

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Discovery of raltegravir, a po ...... eatment of HIV-AIDS infection.

@en

Discovery of raltegravir, a po ...... eatment of HIV-AIDS infection.

@nl

type

label

Discovery of raltegravir, a po ...... eatment of HIV-AIDS infection.

@en

Discovery of raltegravir, a po ...... eatment of HIV-AIDS infection.

@nl

prefLabel

Discovery of raltegravir, a po ...... eatment of HIV-AIDS infection.

@en

Discovery of raltegravir, a po ...... eatment of HIV-AIDS infection.

@nl

P1433

Q46396658-41AA53E6-E7E6-46BE-8787-CEC1B567B62F

P1476

Q46396658-400FE6B8-BAD7-4E86-A475-9C7E26036AF7

P2093

Q46396658-0096BA7D-3907-43EB-8BD0-5E1FB42AAFE4

Q46396658-19EFD87B-6899-4250-B2C2-2DD13764BFF3

Q46396658-3C8D028F-E6CB-4628-A2A0-6DD6B210303E

Q46396658-48D7AB22-211A-4BBF-9921-0A2542D0F71C

Q46396658-513F9D47-9B9E-43E1-A8CE-A067F4BA9458

Q46396658-525CAAA5-7008-45D9-AB4E-FFF636C0BE48

Q46396658-54199D99-4B31-466B-81AE-E3737EBFBB32

Q46396658-62075313-6E65-4DFB-A1AF-3278B7C7973D

Q46396658-6F16D09D-1092-4E37-8E8E-19C836812C24

Q46396658-7D4ECC9E-D621-41CA-9750-BEB6165FFE1F

P304

Q46396658-4A6A4814-FD54-401E-997B-F17D5AD11D72

P31

Q46396658-7CBED253-428B-48F2-95F9-D2C4B4DBD1A1

P356

Q46396658-A2B23424-4B50-4900-BB97-76BCB0A76471

P407

Q46396658-75ED0200-3493-4AD5-A9BD-192B8EB5C270

P433

Q46396658-B701E540-6FDA-4D0A-9F37-AB0D7F7F97C3

P478

Q46396658-F5DF1C89-0A27-4F4F-B069-2C78E2306341

P577

Q46396658-DAB0DB04-8DCE-40CD-9773-B3B17B19B8DB

P698

Q46396658-BD682A0A-2CF6-4F50-8E15-0F9545796843

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of raltegravir, a po ...... eatment of HIV-AIDS infection.

@en

P2093

Alessia Petrocchi

http://www.w3.org/2001/XMLSchema#string

Benedetta Crescenzi

http://www.w3.org/2001/XMLSchema#string

Cristina Gardelli

http://www.w3.org/2001/XMLSchema#string

Daria J Hazuda

http://www.w3.org/2001/XMLSchema#string

Edith Monteagudo

http://www.w3.org/2001/XMLSchema#string

Emanuela Nizi

http://www.w3.org/2001/XMLSchema#string

Ester Muraglia

http://www.w3.org/2001/XMLSchema#string

Fabio Bonelli

http://www.w3.org/2001/XMLSchema#string

Fabrizio Fiore

http://www.w3.org/2001/XMLSchema#string

Federica Orvieto

http://www.w3.org/2001/XMLSchema#string

P304

5843-5855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM800245Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18763751

http://www.w3.org/2001/XMLSchema#string